Abstract Number: 2245 • ACR Convergence 2024
Clinical Efficacy and Molecular Cardiovascular Changes of Baricitinib in Biologic-naïve Patients with Rheumatoid Arthritis. Direct Comparative Analysis with TNF Inhibitors and Conventional DMARDs
Background/Purpose: The main objective of this study was to conduct extensive clinical and molecular analyses to accurately characterize the specific effects of Baricitinib (4 mg/day)…Abstract Number: 0313 • ACR Convergence 2024
Cardiac Sarcoidosis Is Associated with a High Mortality: Retrospective Analysis of a Cohort at Mayo Clinic Florida
Background/Purpose: Sarcoidosis, characterized by non-necrotizing granulomatous inflammation, is a multisystem disease with an unpredictable disease spectrum. An estimated 5% of sarcoidosis patients have clinically evident…Abstract Number: 0647 • ACR Convergence 2024
Clinical Associations and Outcomes of Pericarditis in Systemic Lupus Erythematosus
Background/Purpose: Pericarditis is an important feature in the classification criteria and disease activity assessments in Systemic Lupus Erythematosus (SLE). We aimed to study the prevalence,…Abstract Number: 1011 • ACR Convergence 2024
Use of the Shingrix Vaccine Among Patients with Inflammatory Arthritis and Risk of Cardiovascular Events Following Herpes Zoster
Background/Purpose: The risk of herpes zoster (HZ) is increased in patients with inflammatory arthritis (IA); although the Shingrix vaccine has been available since 2017, its…Abstract Number: 1440 • ACR Convergence 2024
Significant Indicators Identified for Carotid Doppler Ultrasound Use in Axial Spondyloarthritis Patients Without Conventional Cardiovascular Risk Factors
Background/Purpose: The EULAR cardiovascular screening recommendations advocate for the use of carotid dopplers in patients with inflammatory joint diseases to detect subclinical atherosclerosis. Despite these…Abstract Number: 1791 • ACR Convergence 2024
A Transcriptomic Lupus Activity Signature Associates with Cardiovascular Function
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disorder associated with increased cardiovascular risk. Platelet activity is increased in SLE and may mediate, in…Abstract Number: 2259 • ACR Convergence 2024
Effects of Anti-Obesity Medications in RA Patients
Background/Purpose: It is standard practice to advocate for weight loss in patients with rheumatoid arthritis (RA) and obesity. Obesity and rheumatoid arthritis are both independently…Abstract Number: 0331 • ACR Convergence 2024
Cardiac Manifestations in Patients with Anti-Synthetase Syndrome: Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database
Background/Purpose: The prevalence of cardiac manifestations has not been comprehensively described in anti-synthetase syndrome (ASSD). In the current study, we report the prevalence of cardiac…Abstract Number: 0675 • ACR Convergence 2024
Hydroxychloroquine Induced Cardiomyopathy: A Biopsy Proven Case Series
Background/Purpose: Cardiomyopathy is a rare, life-threatening adverse effect of hydroxychloroquine (HCQ) use. There is a paucity in literature regarding treatment and prognosis in these cases. The aim…Abstract Number: 1033 • ACR Convergence 2024
Osteoporosis and Cardiovascular Disease: Mortality Trends Among Adults in the United States from 1999 to 2020
Background/Purpose: Osteoporosis and cardiovascular disease (CVD) represent significant public health concerns. This study investigates the trends and demographic disparities in mortality due to osteoporosis and…Abstract Number: 1463 • ACR Convergence 2024
Investigation of the Cardiometabolic-related Mechanism of Action of Apremilast Through Plasma Proteomics Profiling of Patients with Psoriasis or Psoriatic Arthritis from Three Phase 3 Studies
Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are associated with higher rates of obesity and cardiometabolic complications. Apremilast (APR) is an inhibitor of phosphodiesterase 4,…Abstract Number: 1874 • ACR Convergence 2024
Validation Analysis of the Expanded Risk Score for Rheumatoid Arthritis in a Multicentre Italian Cohort
Background/Purpose: This study aimed to compare the performance of three validated algorithms for 10-year global cardiovascular risk stratification (GCVR): the European Systemic Coronary Risk (SCORE-2)…Abstract Number: 2260 • ACR Convergence 2024
Statin Use in Patients with Rheumatoid Arthritis (RA) and Osteoarthritis: Are RA Patients More Likely to Receive Statins?
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular disease (CVD) partly due to accelerated atherosclerosis from chronic inflammation. However, this increased risk…Abstract Number: 0462 • ACR Convergence 2024
Circulating Mediators of Endothelial Dysfunction as Predictors of Incident Heart Failure in Rheumatoid Arthritis
Background/Purpose: Endothelial dysfunction, leading to myocardial inflammation and dysfunction, may drive a heightened risk of heart failure (HF) in people with rheumatoid arthritis (RA). Circulating…Abstract Number: 0704 • ACR Convergence 2024
Progression of Global Longitudinal Strain and Identification of Left Ventricular Dysfunction in Systemic Sclerosis Patients
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease known for its fibrotic and vascular complications impacting various organs, including the heart. Myocardial involvement causes…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 31
- Next Page »